Trials / Active Not Recruiting
Active Not RecruitingNCT04706598
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer(NMIBC) Failing in BCG Treatment
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of bladder intravesical Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Solution for Infusion (Intravesical) |
Timeline
- Start date
- 2021-06-09
- Primary completion
- 2024-07-11
- Completion
- 2024-12-01
- First posted
- 2021-01-13
- Last updated
- 2024-07-12
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04706598. Inclusion in this directory is not an endorsement.